Thursday, April 16th, 2026

8:30 – 8:50

April 16^th

Christoph Röllig, MD

How to treat FLT3 AML in 2026

University Hospital TU Dresden, Dresden, Germany

8:50 – 9:10

April 16^th

Marina Konopleva, MD

BCL-2 inhibition in AML: successes and challenges

Montefiore Einstein Comprehensive Cancer Center, New York, USA

9:10 – 9:30

April 16^th

Ivana Gojo, MD

Immune therapies in AML

Johns Hopkins University, Leukemia Program, Baltimore, MD, USA

9:30 – 9:40

April 16^th

9:40 – 10:00

April 16^th

Horia Bumbea, MD

Calquence ECHO in Mantle Cell Lymphoma

Department of Hematology at Carol Davila University of Medicine and Pharmacy, Bucharest

10:00 – 10:20

April 16^th

Ioan Macarie MD

I+V: Uniquely built. Strong performance

Târgu Mureș Emergency University Hospital

10:20 – 10:35

April 16^th

10:35 – 10:50

April 16^th

Hermann Einsele, MD Online Talk

Cellular Therapies in MM

University of Würzburg, Germany

10:50 – 11:05

April 16^th

Leo Luznik, MD

Johns Hopkins University, Baltimore, USA

11:05 – 11:20

April 16^th

Sebastian Kobold, MD, PhD

Antibody-adapter-based cellular therapies for acute myeloid leukemia

University Hospital of Ludwig-Maximilian University, Munich, Germany

11:20 – 11:40

April 16^th

Challice Lee Bonifant, MD, PhD

Johns Hopkins University, Baltimore, MD, USA

11:40 – 12:00

April 16^th

Alina Tanase, MD

The CAR-T Access Gap in Europe: Why Geography Still Determines Patient Outcomes

Fundeni Clinical Institute, Bucharest, Romania

12:00 – 1:00

April 16^th

Speakers:

1:00 – 1:20

April 16^th

Ioana Ionița, MD

Advances in first-line therapy of CML - Scemblix - ASC4FIRST

Hematology Department of Municipal Clinical Emergency Hospital of Timisoara

1:20 – 1:40

April 16^th

Iordache Maria MD

Evolving the treatment paradigm with Glofitamab in 3L DLBCL

1:40 – 2:30

April 16^th

2:30 – 2:45

April 16^th

Anca Bojan MD

Tolerability and Efficacy of BrECADD versus BEACOPP in Advanced-Stage Hodgkin Lymphoma

2:45 – 3:00

April 16^th

Ioana Codruta Rus MD

Therapeutic Solutions for Optimizing Prophylaxis and Bleeding Control in Hemophilia A

3:00 – 3:15

April 16^th

Cristina Tarniceriu MD

Acquired Hemophilia: The Invisible Impact Beyond Bruises

3:15 – 3:20

April 16^th

3:20 – 3:40

April 16^th

Popa Delia Codruța

Flow Cytometric Monitoring of CAR-T Cell Therapy: Tracking Immune Dynamics and Relapse Risk

Fundeni Clinical Institute, Bucharest, Romania

3:40 – 4:00

April 16^th

Sonata Saulyte Trakymiene, MD PhD Online Talk

Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania

4:00 – 4:20

April 16^th

Imre Bodó, MD, PhD, DSc

Semmelweis University, Budapest, Hungary

4:20 – 4:40

April 16^th

Ioana Ionița, MD

Victor Babeș University of Medicine, Timișoara, Romania

4:40 – 5:00

April 16^th

5:00 – 5:20

April 16^th

Ciprian Tomuleasa MD

Fit & Young & Free, Calquence and Fix Duration Therapy in Chronic Lymphocytic Leukemia

Department of Hematology – Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania

5:20 – 5:40

April 16^th

Ciprian Tomuleasa MD

Caplacizumab Use in Immune-mediated Thrombotic Thrombocytopenic Purpura: An International Multicentre Retrospective Cohort Study (The Capla 1000+ project)

Department of Hematology – Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania

5:40 – 6:00

April 16^th

Ciprian Tomuleasa MD

Precision and efficiency from the start for patients with acute myeloid leukemia

Department of Hematology – Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania

6:10 – 6:30

April 16^th

Ciprian Tomuleasa MD

Department of Hematology – Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania